Famotidine adjunctive pharmacotherapy of schizophrenia: A case report

R. B. Rosse, K. Kendrick, L. C. Tsui, M. Fay-McCarthy, J. P. Collins, Paul B Rosenberg, R. J. Wyatt, S. I. Deutsch

Research output: Contribution to journalArticle

Abstract

Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporally related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of ~10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone. The case suggests that some adjuvant efficacy exists for famotidine in at least some patients with schizophrenia. Placebo- controlled trials are needed to more fully evaluate the utility of famoditine in the treatment of schizophrenia.

Original languageEnglish (US)
Pages (from-to)369-374
Number of pages6
JournalClinical Neuropharmacology
Volume18
Issue number4
StatePublished - 1995
Externally publishedYes

Fingerprint

Famotidine
Schizophrenia
Drug Therapy
Molindone
Histamine Antagonists
Therapeutics
Antipsychotic Agents
Placebos

Keywords

  • Famotidine
  • H2 antagonist
  • H2 receptor
  • Histamine
  • Schizophrenia

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Rosse, R. B., Kendrick, K., Tsui, L. C., Fay-McCarthy, M., Collins, J. P., Rosenberg, P. B., ... Deutsch, S. I. (1995). Famotidine adjunctive pharmacotherapy of schizophrenia: A case report. Clinical Neuropharmacology, 18(4), 369-374.

Famotidine adjunctive pharmacotherapy of schizophrenia : A case report. / Rosse, R. B.; Kendrick, K.; Tsui, L. C.; Fay-McCarthy, M.; Collins, J. P.; Rosenberg, Paul B; Wyatt, R. J.; Deutsch, S. I.

In: Clinical Neuropharmacology, Vol. 18, No. 4, 1995, p. 369-374.

Research output: Contribution to journalArticle

Rosse, RB, Kendrick, K, Tsui, LC, Fay-McCarthy, M, Collins, JP, Rosenberg, PB, Wyatt, RJ & Deutsch, SI 1995, 'Famotidine adjunctive pharmacotherapy of schizophrenia: A case report', Clinical Neuropharmacology, vol. 18, no. 4, pp. 369-374.
Rosse RB, Kendrick K, Tsui LC, Fay-McCarthy M, Collins JP, Rosenberg PB et al. Famotidine adjunctive pharmacotherapy of schizophrenia: A case report. Clinical Neuropharmacology. 1995;18(4):369-374.
Rosse, R. B. ; Kendrick, K. ; Tsui, L. C. ; Fay-McCarthy, M. ; Collins, J. P. ; Rosenberg, Paul B ; Wyatt, R. J. ; Deutsch, S. I. / Famotidine adjunctive pharmacotherapy of schizophrenia : A case report. In: Clinical Neuropharmacology. 1995 ; Vol. 18, No. 4. pp. 369-374.
@article{10c4cd999a0b401abea3735dcb2aeccb,
title = "Famotidine adjunctive pharmacotherapy of schizophrenia: A case report",
abstract = "Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporally related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of ~10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone. The case suggests that some adjuvant efficacy exists for famotidine in at least some patients with schizophrenia. Placebo- controlled trials are needed to more fully evaluate the utility of famoditine in the treatment of schizophrenia.",
keywords = "Famotidine, H2 antagonist, H2 receptor, Histamine, Schizophrenia",
author = "Rosse, {R. B.} and K. Kendrick and Tsui, {L. C.} and M. Fay-McCarthy and Collins, {J. P.} and Rosenberg, {Paul B} and Wyatt, {R. J.} and Deutsch, {S. I.}",
year = "1995",
language = "English (US)",
volume = "18",
pages = "369--374",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Famotidine adjunctive pharmacotherapy of schizophrenia

T2 - A case report

AU - Rosse, R. B.

AU - Kendrick, K.

AU - Tsui, L. C.

AU - Fay-McCarthy, M.

AU - Collins, J. P.

AU - Rosenberg, Paul B

AU - Wyatt, R. J.

AU - Deutsch, S. I.

PY - 1995

Y1 - 1995

N2 - Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporally related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of ~10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone. The case suggests that some adjuvant efficacy exists for famotidine in at least some patients with schizophrenia. Placebo- controlled trials are needed to more fully evaluate the utility of famoditine in the treatment of schizophrenia.

AB - Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporally related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of ~10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone. The case suggests that some adjuvant efficacy exists for famotidine in at least some patients with schizophrenia. Placebo- controlled trials are needed to more fully evaluate the utility of famoditine in the treatment of schizophrenia.

KW - Famotidine

KW - H2 antagonist

KW - H2 receptor

KW - Histamine

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0029147188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029147188&partnerID=8YFLogxK

M3 - Article

C2 - 8665550

AN - SCOPUS:0029147188

VL - 18

SP - 369

EP - 374

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 4

ER -